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Intervertebral disc (IVD) degeneration is a multifactorial process that is inﬂuenced by contributions from genetic predisposition,
the aging phenomenon, lifestyle conditions, biomechanical loading and activities, and other health factors (such as diabetes).
Attempts to decelerate disc degeneration using various techniques have been reported. However, to date, there has been no proven
technique eﬀective for broad clinical application. Granulocyte colony-stimulating factor (GCSF) is a growth factor cytokine that
hasbeenshowntoenhancetheavailabilityofcirculatinghematopoieticstemcellstothebrainandheartaswellastheircapacityfor
mobilization of mesenchymal bone marrow stem cells. GCSF also exerts signiﬁcant increases in circulating neutrophils as well as
potent anti-inﬂammatory eﬀects. In our study, we hypothesize that GCSF can induce bone marrow stem cells diﬀerentiation and
mobilization to regenerate the degenerated IVD. We found that GCSF had no contribution in disc regeneration or maintenance;
however, there were cell proliferation within end plates. The eﬀects of GCSF treatment on end plates might deserve further
investigation.
1.Introduction
The pathophysiology of disc degeneration is still unknown
[1,2].Clinically,discdegenerationcanbeconsideredasaloss
of proper stability and mobility [3, 4]. Morphologically and
histopathologically, disc degeneration can be characterized
as a decrease in water content associated with proteoglycan
reduction of the nucleus pulposus and inner annulus.
This eﬀect brings on destruction of annular structure and
ﬂattening of the disc [5–7]. In addition, disc tissues have
a limited ability to regenerate, since they are avascular and
nutritionally supported only by passive diﬀusion at the end
plates [2, 8, 9]. Consequently, once the degenerative process
is activated, it is diﬃcult to decelerate and is ultimately
considered to be an irreversible condition [2].
One of the most important elements of disc aging
and degeneration is the well-recognized decline in the
number of disc cells and their products. The experimental
reduction of the proteoglycan content in the nucleus is not
a new concept; chemonucleolysis studies using the enzyme
chymopapain date back over 40 years and were developed
as a treatment for disc herniations through a reduction in
nucleus pulposus pressure [10]. Negative outcomes from
chymopapain led to the introduction of chondroitinase ABC
(ChABC) as a new treatment as this enzyme selectively
degrades chondroitin-4 sulfate, chondroitin-6 sulfate, and
dermatan sulfate glycosaminoglycan chains [11, 12] and is
less aggressive than chymopapain. More recently, after the
observations of a degeneration-like loss of pressure and disc
height [13, 14], ChABC has been speciﬁcally used to induce
degenerative changes using in vivo animal models [15, 16].
Hence, we select this animal model for our experiments.
Administration of granulocyte colony-stimulating factor
(GCSF) is known to mobilize hematopoietic stem cells
(HSCs) from bone marrow into peripheral blood [17].
Peripheral blood-derived HSCs have been used in place of2 Advances in Orthopedics
bone marrow cells in transplantation for the regeneration
of nonhematopoietic tissues such as skeletal muscle and
heart [18]. GCSF has been used extensively for more than
10 years in the treatment of neutropenia as well as for
bone marrow reconstitution and stem cell mobilization [19];
however, it remains unclear whether it is able to stimulates
diﬀerentiation and mobilization of HSCs into the disc tissues
and end plates, and even more, it homes in on intervertebral
disc degeneration to promote disc regeneration or at least
retard the degeneration.
In this study, we use a rat model to test the hypothesis
that GCSF induces HSCs diﬀerentiation and mobilization
to regenerate the degenerated intervertebral discs. We follow
the study up to 6 weeks after experimental induction of disc
degeneration and assess the regenerative eﬀects of the GCSF
treatment using plain radiography, macroscopic ﬁndings,
immunohistochemistry, and confocal laser microscopy.
2.MaterialsandMethods
2.1. Animal Preparations and Induction of Disc Degeneration.
AdultfemaleSprague-Dawleyrats(BioLASCO,Ilan,Taiwan)
weighing 260 ∼ 320g were used. Animals were maintained
for at least 7 days before the experiment in a temperature-
regulated room (23∼25◦C) on a 12h light/dark cycle. Food
was withheld but rats were allowed free access to water
overnight before surgery. All experimental protocols were
in compliance with the NIH G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals and were approved by the Animal Care
and Use Committee of the Chang Gung Memorial Hospital.
After1weekoffacilityacclimation,ratswereoperatedon
using aseptic technique. Rats were anesthetized via intraperi-
toneal injection of Zoletil 1mL/kg (Virbac Animal Health)
and Rompun 0.5mL/kg (Bayer HealthCare), respectively.
On reaching appropriate depth of anesthesia, animals were
placed in a supine position on a heated pad, and an anterior
approach to the lumbar spine was performed.
The lumbar spine from L3 to S1 was exposed, and a
custom 33-gauge needle attached to a gas-tight microsyringe
was inserted through the anterior of the appropriate discs to
a controlled depth of 2.5mm. This insertion depth places
the needle tip approximately in the center of the nucleus
pulposus. Musculature adjacent to the ChABC and sham
PBS injection sites was labeled with a metallic marker for
postoperative level identiﬁcation. The abdominal wall was
closed, and animal recovery was monitored for adverse
symptoms under heated lamp for 45 minutes. Animals were
returned to normal housing and received food and water.
Six weeks after induction of intervertebral disc degen-
eration, the rats of GCSF treatment group were injected
subcutaneously with recombinant human GCSF (50μg/kg
p e rd a y )o n c ed a i l yf o r5d a y s .
2.2. Bromodeoxyuridine Labeling. Bromodeoxyuridine (Brd-
U), a thymidine analogue that is incorporated into the DNA
ofdividingcellsduringS-phase,wasusedformitoticlabeling
(Sigma Chemical). A cumulative labeling method was used
to examine the population of proliferative cells during 5
days of the GCSF treatment. Experimental rats (including
12 normal saline and 12 GCSF treated) were injected
intraperitoneally with BrdU (50mg/kg IP) for 5 consecutive
days, starting the day after vehicles (PBS or GCSF) injection.
2.3. Tissue Preparation. Immediately after sacriﬁce, lumbar
spines were removed en bloc with the ligamentous structures
and posterior bony anatomy remaining intact. Spines desig-
nated for radiographic analysis were wrapped in PBS-soaked
gauze and frozen at −20◦C until lateral plain radiographs
could be performed. Spines designated for histology were
ﬁxed in 10% formalin neutral buﬀer solution (Wako),
decalciﬁed in Plant-Rychlo solution (Decalcifying Solution
A, Wako) and dehydrated in a graded series of ethanol
(70%, 90%, and 99%, Wako). L2/3 discs with vertebral body
units were cut longitudinally at the center of the disc for
macroscopic evaluation. L3/4 discs were harvested mainly
to make frozen sections for immunostaining, and L4/5 discs
were used for proteoglycan evaluation.
2.4. Radiographic Analysis. Lateral plain radiographs were
taken under anesthesia inhalation in all groups before
harvest. Vertebral body heights and disc heights were
measured using NIH image software (NIH, freeware at:
http://rsb.info.nih.gov/nih-image/). The disc height index
(DHI) was calculated for comparisons between groups.
Changes in the DHI were expressed as %DHI and normal-
ized to the measured preoperative IVD height (%DHI =
postoperative DHI/preoperative DHI × 100).
2.5. Immunohistochemistry. To identify the expression of cell
type-speciﬁc markers in BrdU+cells, double immunoﬂuo-
rescence was performed. The rat monoclonal anti-CD34
antibody (CD34, 1:200, Acris Antibodies GmbH, Hidden-
hausen, Germany) was used. Each transverse section was
ﬁrst treated with primary BrdU antibody conjugated with
FITC (1:500, Jackson Immunoresearch) staining, followed
by treatment with CD34 antibodies with Cy3 (1:500,
JacksonImmunoresearch)staining. Thepositive signalswere
observed by ﬂuorescence microscope. We also used confocal
laser scanning microscope to observe BrdU and CD34-
double positive cells more clearly.
Proteoglycan accumulation changes in the discs were
studied to evaluate disc degeneration. The sections were
labeled overnight at 4◦C with antirat proteoglycan mono-
clonal antibody (Chemicon, Temecula, CA, USA), prepared
at a dilution of 1:200 in PBS. The samples were washed with
PBSthreetimesandreactedwithantimouseHRP(DakoA/S,
Profuktionsvej, Denmark) at a dilution of 1:100 in PBS for
30min at 4◦C. Finally, the sections were counterstained with
hematoxylin for histologic examination.
2.6. Confocal Laser Microscopy. In order to visualize changes
in proteoglycan accumulation more clearly, the sections
labeled with proteoglycan antibodies were stained with
antigoat Alexa ﬂuors 488 (Molecular Probes, Eugene, OR,
USA) a ﬂuorescent second antibody and evaluated under
confocal laser scanning microscopy. Statistical analyses were
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Figure 1: Intervertebral disc height (DHI) was calculated by averaging the measurements obtained from the anterior, middle, and posterior
portions ofthe IVDand dividing that by the average of adjacent vertebral body heights. We foundChABC injection resulted inno signiﬁcant
change at 3 weeks after injection; however, some early osteophyte formation with decrease in DHI was disclosed at 6 weeks after injection.
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the GCSF treatment group showed increasing Safranin O staining over end plates even more than normal control group.
BrdU CD34 Hochest Merged
402µm4 0 2 µm4 0 2 µm4 0 2 µm
Figure 4: Some positive BrdU staining around the end plates in the GCSF treatment group, however, no apparent CD34 costaining were
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rank test using Stat View software. Signiﬁcance in all cases
were set at P<. 05.
3. Results
3.1. Radiographic Analysis. Using digitized radiographs,
measurements including the vertebral body height and IVD
height were analyzed. Intervertebral disc height (DHI) was
calculated by averaging the measurements obtained from
the anterior, middle, and posterior portions of the IVD
and dividing that by the average of adjacent vertebral body
heights.WefoundChABCinjectionresultedinnosigniﬁcant
change at 3 weeks after injection; however, some early
osteophyte formation with decrease in DHI was disclosed at
6 weeks after injection (Figure 1).
3.2.Immunohistochemistry. Loosenedarrangementwithdis-
organization of nucleus pulposus (NP) was noted after
ChABC injection on H & E staining (Figure 2). However,
therewerenosigniﬁcantchangesofNPafterGCSFtreatment
than sham-operated treatment on the Safranin O staining. It
is worth mentioning that the GCSF treatment group showed
increasing Safranin O staining over end plates even more
than normal control group (Figure 3).
3.3. Double Immunoﬂuorescence. Although we could ﬁnd
some positive BrdU staining around the end plates in the
GCSF treatment group, no apparent CD34 costaining were
disclosed (Figure 4).
4. Discussion
Histopathologically, the IVD degeneration shows a decrease
in water content associated with reduced proteoglycan con-
tent of the nucleus pulposus, resulting in destruction of the
annularstructureandﬂatteningofthedisc.Althoughwehad
found decrease in DHI since 6 weeks after ChABC injection,
the results showed no statistical signiﬁcance. Probably longer
time interval and larger data base are needed for statistic
analysis.
Recent advances in molecular biology have provided
new knowledge on the nature of the IVD and disc cells.
Experimental studies on disc cell function have enabled
scientists and clinicians to develop new approaches for
the treatment of disc degeneration and regeneration [20].
Currently, strategies to regenerate the disc focus on restoring
the ability to regulate matrix production and to restore
the disc tissue. In these strategies, autologous NP cell
transplantation has become one of the major techniques
in attempts to prevent IVD degeneration in animal models
[21, 22]. However, it has been considered diﬃcult for broad
application clinically. In our study, we hypothesize that
GCSF can induce bone marrow stem cells diﬀerentiation
and mobilization to regenerate the degenerated IVD. We
foundthatGCSFhadnocontributionindiscregenerationor
maintenance; however, there were some increasing staining
and cell proliferation within end plates. The eﬀects of GCSF
treatment on end plates might deserve further investigation.
5. Conclusions
Inourstudy,wefoundthatGCSFhadnocontributionindisc
regeneration or maintenance after induction of disc degen-
eration for 6 weeks; however, there were cell proliferation
within end plates. The eﬀects of GCSF treatment on end
plates might deserve further investigation.
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